Grace Therapeutics, Inc.
Last 30 daysInsiders bought $417.81K · 2 buyers, led by Prashant Kohli (CEO) with $214K. No qualifying insider sales.
Showing the first 6 of 8 trades on this page.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
VP Program Management
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Executive Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Medical Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Principal Financial Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Stock Option (Right to Buy)Grant or award | Derivative units12,200Award · no purchase price | Non-cash award | Sep 17Filed Sep 21 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative unitsUnavailableAward · no purchase price | Non-cash award | Sep 17Filed Sep 21 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units12,200Award · no purchase price | Non-cash award | Sep 17Filed Sep 21 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units12,200Award · no purchase price | Non-cash award | Sep 17Filed Sep 21 · 4d later | SEC filing |
| VP Program Management | Stock Option (Right to Buy)Grant or award | Derivative units35,760Award · no purchase price | Non-cash award | Aug 28Filed Sep 1 · 4d later | SEC filing |
| Chief Executive Officer | Stock Option (Right to Buy)Grant or award | Derivative units267,160Award · no purchase price | Non-cash award | Aug 28Filed Sep 1 · 4d later | SEC filing |
| Chief Medical Officer | Stock Option (Right to Buy)Grant or award | Derivative units54,690Award · no purchase price | Non-cash award | Aug 28Filed Sep 1 · 4d later | SEC filing |
| Principal Financial Officer | Stock Option (Right to Buy)Grant or award | Derivative units33,660Award · no purchase price | Non-cash award | Aug 28Filed Sep 1 · 4d later | SEC filing |
This reflects the filings imported so far, not a complete trading history.
$408,202 of common-equity purchase value after transaction-age decay across 180 days.
2 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
2 buying groups inside 30 transaction-date days, public by the snapshot cutoff.
A reporting-owner group bought on at least two distinct dates within the cluster window.
At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
